Another Brick to Confirm the Efficacy of Rigosertib as Anticancer Agent
Sign Up to like & getrecommendations! Published in 2023 at "International Journal of Molecular Sciences"
DOI: 10.3390/ijms24021721
Abstract: Rigosertib is a small molecule in preclinical development that, due to its characteristics as a dual PLK1 and PI3K inhibitor, is particularly effective in counteracting the advance of different types of tumors. In this work,… read more here.
Keywords: cell; another brick; agent; efficacy ... See more keywords